What is in your differential diagnosis when considering recurrent C difficile infections? How is a definitive diagnosis made?

The panelist discusses how recurrent Clostridioides difficile infection significantly increases health care costs through prolonged hospitalizations, complex treatments, and elevated medical resource ...

Zinplava ™ (bezlotoxumab) injection will be discontinued as of January 31, 2025, according to the Food and Drug Administration’s (FDA) drug shortages tracker.

Clostridioides difficile (C. diff) is a bacterial infection that commonly affects people with ulcerative colitis (UC). It can worsen symptoms and cause complications. It can also trigger a ...

Xeno Biosciences may have been unable to prove that its drug delivering oxygen to the gastrointestinal tract can induce ...

The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...

Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...

Pfizer advances second-generation C. diff vaccine with Phase 2 data expected in 2025. Analyst maintains cautious optimism as investor sentiment remains muted on vaccine efforts. Pfizer hosted a ...

"We are excited to advance Xeno's technology in a new therapeutic direction and to begin a pivotal Phase II study as we secure funding to support our clinical goals," said Larry Sutton, MD, PhD, ...

In fecal transplant, bacteria from a healthy person’s gut is transferred into a person with GI problems. The procedure is ...

Pharmaceuticals is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for ...